Company / PP&E (Net)
Idexx Laboratories PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$747.4M
FY2025
5-year range
$587.7M / $747.4M
FY2021-FY2025
Trend
+4.8%
vs FY2024
Sector context
#41 of 135
Health Care
What the data says
At $747M, Idexx Laboratories's pp&e (net) ranks #41 of 135 in the Health Care sector. PP&E (Net) has increased for 9 consecutive years, from $357M in FY2016 to $747M in FY2025.
Based on SEC 10-K filings.
$747M in FY2025 with a 5-year CAGR of +6.1%.
Improved from $702M to $747M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +4.8%
- 5-Year CAGR
- +6.1%
- 10-Year CAGR
- -
Sector benchmark
#41 of 135 in Health CareTop 30% of 135This company $747.4M Sector average $1.4B
▼
-45.1% below sector average
Key checks
Key Insights
- Idexx Laboratories's pp&e (net) has grown for 9 consecutive years.
- 5-year CAGR of +6.1%, indicating consistent growth.
- In FY2025, pp&e (net) increased 4.8% year-over-year.
- Ranks #41 out of 135 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $747.4M | +4.8% |
| FY2024 | $713.1M | +1.6% |
| FY2023 | $702.2M | +8.1% |
| FY2022 | $649.5M | +10.5% |
| FY2021 | $587.7M | +5.9% |
| FY2020 | $555.2M | +4.0% |
| FY2019 | $533.8M | +22.1% |
| FY2018 | $437.3M | +15.3% |
| FY2017 | $379.1M | +6.1% |
| FY2016 | $357.4M | +7.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026